Abstract
Recently, red blood cell transfusions have been advocated for patients with acute myocardial infarction when hemoglobin falls below 10 g/dL, based on the Myocardial Ischemia and Transfusion (MINT) trial, which showed a trend to benefit, compared to deferring transfusion until hemoglobin was below 7-8 g/dL. However, the trial failed to reach its primary endpoint. A meta-analysis including the totality of published relevant evidence does not support the superiority of one blood transfusion strategy over another. Advocating a policy of more liberal transfusion for patients with myocardial infarction and anemia is premature, potentially erroneous, and harmful.
References
Downloads
pdf
Authors
Aryeh Shander TeamHealth Department of Anesthesiology and Critical Care, Englewood Health, New Jersey, United States of America
Kevin M. Trentino
Medical School, The University of Western Australia, Perth, Australia
Caroline Evans Department of Anaesthesia and Intensive Care, University Hospital of Wales, Cardiff, United Kingdom
John Cleland
British Heart Foundation Centre of Research Excellence. School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom
- Abstract viewed - 1113 times
- pdf downloaded - 0 times